Current antivirals not successful in treating severe H5N1 bird flu infections

As the H5N1 avian influenza outbreak continues, scientists are working to better understand the virus's threat to human...

NIH researchers define topical steroid withdrawal diagnostic criteria

Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid withdrawal (TSW)...

Common medicines contain hidden gluten and soy, study finds

Researchers reveal that widely used pain and fever medicines may harbor undeclared gluten or soy ingredients—raising concerns for...

Older adults may have stronger immunity to bird flu, Penn study finds

Prior exposures to specific types of seasonal influenza viruses promote cross-reactive immunity against the H5N1 avian influenza virus,...

Аллергия на холод: миф или реальность? Симптомы и методы защиты

Многие слышали о странной реакции кожи на мороз — покраснение, зуд, волдыри, напоминающие ожог крапивой. Некоторые считают это...

NIH clinical trial examines investigational therapy for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to...

Influenza A virus changes shape to evade immune responses

Influenza A virus particles strategically adapt their shape-to become either spheres or larger filaments-to favor their ability to...

New CT-based score helps predict need for repeat sinus surgery

A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery...

Early exposure to food allergens could prevent severe reactions in children

A review in Clinical & Experimental Allergy concludes that exposing young children to small amounts of foods that...

Granzyme K identified as key trigger of complement system in autoimmune diseases

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One...

EBV exposure linked to life-threatening cancer risk in kidney transplant patients

More than 90% of the adult population in the U.S. is or has been infected with Epstein Barr...

HHS and NIH announce the development of next-generation, universal vaccine platform

Colorized transmission electron micrograph of influenza A/H1N1 virus particles. The U.S. Department of Health and Human Services (HHS)...

Gut immune cells linked to worsening rheumatoid arthritis

After spending years tracing the origin and migration pattern of an unusual type of immune cell in mice,...

Asthma and allergy rates higher among First Nations people in Australia

Researchers at The University of Queensland have found First Nations people are twice as likely to present at...

Omalizumab outperforms oral immunotherapy in treating multi-food allergy

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than...

Genomic sequencing-based detection system cuts infections and saves lives

An infectious diseases detection platform developed by University of Pittsburgh scientists working with UPMC infection preventionists proved over...

Bach2 protein identified as key regulator in atopic dermatitis

Atopic dermatitis is an allergy affecting approximately 10% of the Japanese population, with symptoms closely related to social...

Study explores how nanoplastics could affect child’s immune system during pregnancy

Allergies and asthma are widespread diseases that could arise during embryonal development in the womb. A team led...

Supplements over salmon? Study finds pregnant women choose capsules over food

Despite the widespread use of fish oil and probiotics during pregnancy, many women remain confused about national guidelines...

Material from nasal lavage provides a basis for assessing COPD

Early diagnosis of COPD, chronic obstructive pulmonary disease, increases the quality of life of the patient and the...

Beckman coulter’s new basophil activation test for allergies

Innovation Follows $1 Million FARE Award.

Image Credit: Beckman Coulter Life Sciences

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, introduces the Next-Generation Basophil Activation Test (BAT) for research use only to more effectively characterize food allergies without exposure to potentially harmful allergens.

Approximately 220 million people globally suffer from at least one food allergy. Most food allergies and treatment efficacies are currently determined through a dated and rigorous Oral Food Challenge (OFC), exposing a patient to gradual amounts of foods to determine if they have a reaction, which could include anaphylaxis in some situations. The new BAT test eliminates that risk, testing for multiple allergens at once through a blood draw — saving hours of food testing and exposure to potentially harmful reactions.

This offers a groundbreaking alternative in allergy testing, removing patient obstacles and reducing ethical concerns associated with direct allergen exposure in vulnerable participants,”

Jean-Marc Busnel, PhD, Principal Investigator and Senior Staff Research Scientist, Beckman Coulter Life Sciences

“For too long these concerns have limited critical advancements, putting people at risk of not having access to life-saving treatment options should an allergic reaction occur. By removing these barriers, this test unlocks an opportunity to finally expand food allergy drug development and research. This reinforces our mission at Beckman Coulter Life Sciences to deliver tools that empower clinicians and improve patient outcomes.”

The innovation follows the FARE (Food Allergy Research and Education) Innovation Award Diagnostic Challenge which Beckman Coulter Life Sciences received in 2022. The $1 million award helps foster the development of improved testing methods in the field of food allergies.

“At FARE, we have prioritized supporting the development of safer alternatives to oral food challenges that can expose patients to risk and induce anxiety,” said Sung Poblete, PhD, RN, CEO of FARE. “The introduction of this next-generation Basophil Activation Test marks a significant advancement, moving diagnostic innovation from the bench toward future clinical application, paving the way for safer, more accessible food allergy research while offering the opportunity to stimulate progress and we are excited about the promise it holds for research and development.”

BAT are functional assays measuring basophil activation in response to specific allergens or other stimuli.

By leveraging dry technology to overcome traditional BAT challenges, standardization is enabled with conjugated antibodies and allergens pre-mixed and dried down together in a single tube with only 4 pipetting steps. Negative and positive controls can also be included, all without the need for compensation or centrifugation, and is compatible with any flow cytometer.

While BAT has been around for more than 30 years and provides valuable insights in the study of allergies, its adoption has been limited due to the perceived complexity and lack of reproducibility associated with the assay. The use of dry reagents can support overcoming those challenges.

The test offers unmatched flexibility with customizable dried down allergens, antibodies, and concentrations available through Custom Design Service from Beckman Coulter Life Sciences.

Image Credit: Beckman Coulter Life Sciences

About Beckman Coulter Life Sciences

Time is the most critical facet in the laboratory today:  time to get life-saving therapies to patients faster; reclaiming time by automating tedious manual workflows; and saving time otherwise spent addressing erroneous or complex results.

At Beckman Coulter Life Sciences, we are partners in time. We accelerate answers to critical questions through the power of efficiency, saving hours from some workflows and delivering reliable results in centrifugation, flow cytometry, genomic solutions, particle analysis/counters, and liquid handlers.

We develop innovations for scientists by scientists, with many of our 3,300+ global colleagues coming from the laboratory with a deep understanding of today’s challenges and complexities. We’re passionate about translating science in partnership with our customers, and our customizable, accessible and sustainable solutions empower them with intuitive workflow efficiencies.

Time and again customers put their trust in us, with 400,000+ of our built-to-last products currently delivering results in labs worldwide – all backed by our dependable service and application experts offering educational insights and tailored support.

It’s all part of our time-tested approach since 1935 to bring meaningful innovations at the speed of life—and we’re just beginning. Working together, let’s advance human health for a better tomorrow!

Get to know us by clicking here and by following us on LinkedIn.

Source:

Beckman Coulter Life Sciences


Source: http://www.news-medical.net/news/20250408/Beckman-Coulter-Life-Sciences-launches-safer-Next-Generation-Basophil-Activation-Test-to-improve-expedite-allergy-research.aspx

Inline Feedbacks
View all comments
guest